#APRI - Still on watch for me. Near 52-week lows. Company has a novel erectile dysfunction topically applied cream that they are seeking FDA approval for. Approval was denied in mid-February which resulted in significant share price decrease. According to company PR dated March 1, 2018, they plan to meet again with FDA for further guidance in April. This is a NASDAQ company with significant upside IMO should good news come out. Would certainly welcome others' opinions.